Calidi Biotherapeutics Inc (CLDI) - News Archive

Showing 9 of 9 results.

Calidi Biotherapeutics Strengthens Cash Reserves with New Investor Agreement, Advancing Targeted Immunotherapy Efforts,

Calidi Biotherapeutics Expands Its Horizons with New Securities Agreement: A Step Forward in Targeted Immunotherapy DevelopmentIn a move signaling confidence from investors in the field of innovative cancer therapies, C...

Mar 28, 2025 • Biotechnology & Pharmaceuticals Industry Shares immunotherapy

Calidi Biotherapeutics Secures $4.25 Million in Public Offering: Accelerating the Future of Targeted Cancer Therapies,

Calidi Biotherapeutics: Navigating the Future of Cancer Therapy with New Funding and Promising Advances in VirotherapySAN DIEGO, Jan. 10, 2025 Calidi Biotherapeutics Inc. (NYSE American: CLDI), a pioneering clinical-sta...

Jan 10, 2025 • Biotechnology & Pharmaceuticals Industry Financing Agreement immunotherapy

Calidi Biotherapeutics Seizes Funding Opportunity: $4.25 Million to Propel Targeted Cancer Therapy Development,

Calidi Biotherapeutics Secures $4.25 Million in Public Offering: Accelerating the Future of Targeted Cancer TherapiesOn January 10, 2025, Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI), a clinical-stage biotechnolog...

Jan 10, 2025 • Biotechnology & Pharmaceuticals Industry Shares oncolytic virus

Unleashing the Future of Cancer Care How Calidi Biotherapeutics RTNova Technology is Targeting Metastatic Lung Cance...

Revolutionizing Targeted Cancer Therapy: Calidi Biotherapeutics Promising Data on RTNova Technology for Metastatic Lung Cancer In recent years, the field of oncology has witnessed remarkable advancements in targeted the...

Nov 18, 2024 • Biotechnology & Pharmaceuticals Industry Product Service News immunotherapyAmerican Calidi Calidi C However

Calidi Biotherapeutics Secures $7.5 Million from Public Offering to Propel Antitumor Virotherapy Development,

Calidi Biotherapeutics Reaches Financial Milestone with $7.5 Million Public Offering: A Strategic Move in Targeted Antitumor VirotherapiesSan Diego-based Calidi Biotherapeutics Inc. (NYSE American: CLDI), a forward-thin...

Nov 15, 2024 • Biotechnology & Pharmaceuticals Industry Shares immunotherapy

Calidi Biotherapeutics Faces NYSE Delisting of Warrants Amid Advancements in Virotherapy for Brain Cancer

In a significant development for Calidi Biotherapeutics, Inc. a clinical-stage biotechnology company poised to innovate the treatment of high-grade glioma, the NYSE Regulation staff has initiated proceedings to delist t...

Oct 19, 2024 • Biotechnology & Pharmaceuticals Industry Shares

Advancing Hope in High-Grade Glioma Treatment FDA Clearance of CLD-101 Clinical Trial by Calidi Biotherapeutics

In an exciting development for the realm of neuro-oncology, Calidi Biotherapeutics has announced FDA clearance for its Investigational New Drug (IND) application for CLD-101, a promising treatment aimed at newly diagnos...

Sep 30, 2024 • Biotechnology & Pharmaceuticals Industry Clinical Study virotherapyCalidi Biotherapeutics Inc Calidi Bioth

Calidi Biotherapeutics Receives Financial Boost to Revolutionize Cancer Therapies

Calidi Biotherapeutics Secures $3 Million Investment from Dr. Ronald Rigor for Nova Cell Subsidiary Development and Oncology Pipeline ExpansionSan Diego-based biotechnology company, Calidi Biotherapeutics, has announced...

Jul 29, 2024 • Biotechnology & Pharmaceuticals Industry Financing Agreement immunotherapy

Dr. Mark Gilbert Joins Calidi Biotherapeutics' Medical Advisory Board, Bringing In-Depth Government Healthcare Agency Expertise

IntroductionIn a recent press release, Calidi Biotherapeutics Inc, a leading biopharmaceutical company focused on developing innovative cell-based immunotherapies, announced the appointment of Dr. Mark Gilbert to its es...

Jul 16, 2024 • Biotechnology & Pharmaceuticals Industry Management Changes immunotherapy